Amyloid Peptides by LifeTein
Peptide science is expanding rapidly due to the potential applications of these biocompatible and bioactive molecules. However, their use in medicine is limited by several factors, with low solubility being a significant hurdle in early drug development. Solubility is crucial but not well understood, and no universal method exists for peptide solubilization. This review examines the challenges in dissolving peptides and the factors influencing their aggregation and evaluates various solubilization strategies. Here are some practical tips for handling difficult sequences, with a focus on challenging amyloids like amyloid beta (Aβ), insulin, and phenol-soluble modulins (PSMs). Download the reference Here.
At LifeTein, we specialize in synthesizing high-quality amyloid peptides to support Alzheimer's disease research. Alzheimer's disease is characterized by the accumulation of extracellular amyloid-β peptides in the brain, forming plaques, and the development of intracellular neurofibrillary tangles. These pathologies are associated with the progressive loss of neurons, leading to a decline in cognitive functions and behavioral disturbances.
Alzheimer’s disease primarily affects individuals over the age of 60, with the risk increasing significantly with age. As populations in developed and emerging countries continue to age, Alzheimer’s has become a major health and social challenge. Over 46 million people worldwide suffer from this irreversible and progressive neurodegenerative disorder, with symptoms that include memory loss, impaired verbal and visuospatial abilities, and changes in personality and behavior. In the final stages, patients are entirely dependent on caregivers.
Our service focuses on synthesizing key amyloid peptides, such as amyloid-beta (1-42), which is a crucial component of amyloid plaques found in Alzheimer's patients. These peptides are generated from the cleavage of amyloid precursor protein (APP) by β- and γ-secretases. Amyloid-β (1-42) is particularly significant due to its higher propensity to form plaques compared to amyloid-β (1-40).
Understanding the molecular mechanisms underlying Alzheimer’s disease has been essential for developing diagnostic tools and therapeutic strategies. Currently, diagnosis is achieved with about 90% accuracy through a combination of neurological and psychiatric evaluations, neuropsychological tests, and advanced imaging techniques. Despite these advancements, a definitive diagnosis can only be made through post-mortem examination of brain tissue.
Research has identified various genetic factors associated with both early-onset and late-onset Alzheimer’s disease. Mutations in the APP, presenilin-1, and presenilin-2 genes are linked to familial forms of the disease, while the APOEε4 allele has been associated with increased risk for late-onset Alzheimer’s.
At LifeTein, we provide a range of amyloid peptides to aid researchers in unraveling the complexities of Alzheimer’s disease and developing effective treatments. Our commitment to quality and precision in peptide synthesis ensures that researchers have the reliable tools they need to advance their studies and contribute to the fight against this debilitating disease.
Reference:
Polanska O, Szulc N, Stottko R, Olek M, Nadwodna J, Gasior-Giogowska M, Szefczyk M. Challenges in Peptide Solubilization - Amyloids Case Study. Chem Rec. 2024 Jul 18:e202400053. doi: 10.1002/tcr.202400053. Epub ahead of print. PMID: 39023378.
